CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
Enzalutamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01534052
NCT01534052Phase 2Completed
CompareCT.gov

A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

Astellas Pharma Inc·interventional·Posted Feb 16, 2012·Updated Dec 6, 2024

In Brief

A Phase 2 clinical trial evaluating Enzalutamide for Castration-Resistant Prostate Cancer (CRPC). Completed, enrolled 52 participants across 7 sites in 3 countries.

Detailed Summary

A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCastration-Resistant Prostate Cancer (CRPC)
CountriesMoldova, South Africa, United States
CollaboratorsMedivation LLC, a wholly owned subsidiary of Pfizer Inc.

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 16, 2012
Enrollment StartOct 21, 2011
Primary CompletionApr 18, 2017
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 14.4 years ago

Interventions

Enzalutamidedrug

Oral